DICE Therapeutics, Inc.
http://www.dicemolecules.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DICE Therapeutics, Inc.
Lilly To Bolster IBD Pipeline With $3.2bn Morphic Bid
With only one inflammatory bowel disease product, Lilly is betting big on Morphic and its Phase II oral integrin MORF-057, which would directly compete with Takeda blockbuster Entyvio.
Finance Watch: Lilly’s Gateway Labs, Deerfield’s Cure Offer Biotechs Space To Grow
Private Company Edition: Scrip spoke with the leaders of Gateway Labs and Cure at the BIO International Convention about their mini ecosystems. Also, radiopharmaceutical firm ITM raised €188m ($201.9m), Santa Ana Bio emerged with $168m and Alzheon’s series E totaled $100m.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest
Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Technologies
- Molecular Diversity
-
Drug Discovery Technologies
- Other Names / Subsidiaries
-
- DiCE Molecules SV LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice